Last reviewed · How we verify
Enasidenib, dexamethasone, ixazomib, pomalidomide
Enasidenib, dexamethasone, ixazomib, pomalidomide is a Small molecule drug developed by Multiple Myeloma Research Consortium. It is currently in Phase 1 development. Also known as: enasidenib: AG221, IDHIFA, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst.
At a glance
| Generic name | Enasidenib, dexamethasone, ixazomib, pomalidomide |
|---|---|
| Also known as | enasidenib: AG221, IDHIFA, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst |
| Sponsor | Multiple Myeloma Research Consortium |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Myeloma-Developing Regimens Using Genomics (MyDRUG) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enasidenib, dexamethasone, ixazomib, pomalidomide CI brief — competitive landscape report
- Enasidenib, dexamethasone, ixazomib, pomalidomide updates RSS · CI watch RSS
- Multiple Myeloma Research Consortium portfolio CI
Frequently asked questions about Enasidenib, dexamethasone, ixazomib, pomalidomide
What is Enasidenib, dexamethasone, ixazomib, pomalidomide?
Enasidenib, dexamethasone, ixazomib, pomalidomide is a Small molecule drug developed by Multiple Myeloma Research Consortium.
Who makes Enasidenib, dexamethasone, ixazomib, pomalidomide?
Enasidenib, dexamethasone, ixazomib, pomalidomide is developed by Multiple Myeloma Research Consortium (see full Multiple Myeloma Research Consortium pipeline at /company/multiple-myeloma-research-consortium).
Is Enasidenib, dexamethasone, ixazomib, pomalidomide also known as anything else?
Enasidenib, dexamethasone, ixazomib, pomalidomide is also known as enasidenib: AG221, IDHIFA, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst.
What development phase is Enasidenib, dexamethasone, ixazomib, pomalidomide in?
Enasidenib, dexamethasone, ixazomib, pomalidomide is in Phase 1.
Related
- Manufacturer: Multiple Myeloma Research Consortium — full pipeline
- Also known as: enasidenib: AG221, IDHIFA, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst